| Dunlap Vision Center | |
| 303 Salisbury Ave, Albemarle, North Carolina 28001 | |
| (704) 982-6011 |
| Name | Dunlap Vision Center |
|---|---|
| Organization Name | Thomas E Dunlap Jr |
| Location | 303 Salisbury Ave, Albemarle, North Carolina 28001 |
| Type | Supplier |
| Phone | (704) 982-6011 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
Today, the success of the Young Investigator Grant for Probiotics Research (YIGPRO) program was confirmed with the announcement of two $50,000 grants that are available to rising young investigators in the field of probiotics. 2010 marks the third consecutive year for the grants. The grants were established by The Global Probiotics Council (GPC), a committee formed by DANONE and Yakult Honsha Co., Ltd., and are designed to contribute to the advancement of probiotics and gastrointestinal microbiota research in the United States.
RemitDATA, Inc., a leading provider of web-based productivity tools and benchmarking to the outpatient healthcare market, today announced that Texas Academy of Family Physicians (TAFP), the largest medical specialty organization, serving over 5,500 family physicians in Texas, has joined forces with RemitDATA to aggregate members' reimbursement data and provide real-time payer benchmarking to help TAFP identify problematic payers and troubling reimbursement trends before they turn into cash-flow pitfalls.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
› Verified 8 days ago
News Archive
A healthcare 'passport' to access NHS and other wellbeing services has been beneficial for the mental health of veterans and provides them with a sense of identity, according to research published in the BMJ Military Health.
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
Today, the success of the Young Investigator Grant for Probiotics Research (YIGPRO) program was confirmed with the announcement of two $50,000 grants that are available to rising young investigators in the field of probiotics. 2010 marks the third consecutive year for the grants. The grants were established by The Global Probiotics Council (GPC), a committee formed by DANONE and Yakult Honsha Co., Ltd., and are designed to contribute to the advancement of probiotics and gastrointestinal microbiota research in the United States.
RemitDATA, Inc., a leading provider of web-based productivity tools and benchmarking to the outpatient healthcare market, today announced that Texas Academy of Family Physicians (TAFP), the largest medical specialty organization, serving over 5,500 family physicians in Texas, has joined forces with RemitDATA to aggregate members' reimbursement data and provide real-time payer benchmarking to help TAFP identify problematic payers and troubling reimbursement trends before they turn into cash-flow pitfalls.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
› Verified 8 days ago
Atrium Health At Home Hme Stanly Type: Durable Medical Equipment & Medical Supplies Supplier Location: 907 N 2nd St, Albemarle, North Carolina 28001 Phone: (980) 323-5280 | |
Community Pharmacy Of Albemarle Llc Type: Pharmacy Location: 320 Yadkin St, Albemarle, North Carolina 28001 Phone: (704) 982-9179 | |
Dr James L Marshall Type: Eyewear Supplier (Equipment, not the service) Location: 1003 N 1st St, Albemarle, North Carolina 28001 Phone: (704) 983-2202 | |
Adult And Pediatric Specialists Type: Durable Medical Equipment & Medical Supplies Supplier Location: 746 N 2nd St, Albemarle, North Carolina 28001 Phone: (704) 986-4342 | |
Samuel E Thompson, Od Type: Medicare Supplier Location: 615 B Henson St, Albemarle, North Carolina 28001 Phone: (704) 982-2020 |